Currently, at least three clinical trials are underway to investigate the addition of Ruxolitinib to combination chemotherapy in CRLF2 rearranged/JAK aberrant Ph-like B-ALL (NCT02723994, NCT03117751, NCT02420717). Here, CRLF2 is linked to acute lymphoblastic leukemia.